Skip to content
Medical Health Aged Care

Phebra Group establishes new subsidiary pharma company: ‘Phero Pharma’ will fill medical shortages in the Australian health system

Phebra Group 2 mins read

Leading Australian pharmaceutical firm Phebra Group (‘Phebra’) is delighted to announce the establishment of a new subsidiary, Phero Pharma Pty Ltd (‘Phero  Pharma’). Phero will focus on identifying opportunities for in-licensing of products to address pharmaceutical needs across the Australian healthcare system.

 

“The Phebra Group is very excited about the creation of this company, Phero Pharma,” Phebra Chief Executive Officer, Andre Vlok, said today.

 

“As an Australian-based manufacturer, Phebra has been operating in Australia for over 30 years, working closely with clinicians, hospitals, and research facilities to develop niche products, including a range of critical medicines.

 

“Australia has long been vulnerable to global supply chain disruptions which have led to local pharmaceutical shortages. Phebra has been called upon over several years to successfully supply drugs with limited, or no market supply.

 

“We believe the establishment of Phero will enable us to focus on these market opportunities where we can provide safe and quality therapeutic solutions for Australian patients and allied health stakeholders, through an agile approach to in-licensing and manufacture from reputable sources. Phero is a next phase of the Phebra journey that began in Sydney three decades ago.”

 

Phero Pharma is a wholly owned subsidiary of Phebra Group which will operate as an entirely separate business unit with its own brand and value proposition. Phero’s newly appointed General Manager, Roger Darlington, brings nearly 30 years’ experience both in the pharmaceutical industry, medical software, and device space.

 

Roger recently held the Commercial Manager role at Mundipharma Pty Ltd where he was responsible for contracts and tenders and led Mundipharma’s external stakeholder relationships and Ophthalmology business. Prior to Mundipharma, he led the ANZ commercial activity for several leading MedTech and medical software companies.

 

“I am thrilled to be heading up Phero as we focus on identifying, sourcing, and listing products and collaborating with the TGA to address shortages of important pharmaceuticals in Australia,” he explained.

 

“While it may sound a cliché, I have always sought to add value and to make a difference in the Australian marketplace; that’s my passion and we are committed to doing that at Phero.”

 

Phero commenced operations on 1 March, 2024.


Key Facts:

To contact Roger Darlington, use rdarlington@Pheropharma.com

 

About Phero

 

Phero is an Australian pharmaceutical company focused on the in-licensing of products aimed at meeting patient needs for better healthcare outcomes. 

 

Editor’s note: Phero is the Greek word, ‘to bring’, ‘bear’, ‘carry’.

 

About Phebra

 

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

 

At Phebra, we create critical medicines that save and improve lives.

 


Contact details:

Media contact:

Richard Lenarduzzi. +61 411 254 390

More from this category

  • Medical Health Aged Care
  • 25/04/2024
  • 09:05
Royal Australian College of GPs

More needs to be done for veterans missing out on care

More can be done to ensure veterans can access the care they need for chronic conditions, says the Royal Australian College of GPs (RACGP). In a submission to an independent evaluation of the Coordinated Veterans’ Care (CVC) Program, the peak body for GPs called for improvements to the scheme to help veterans access care. The CVC provides funding for care coordination in general practice for Veteran Gold Card holders with chronic conditions and Veteran White Card holders with chronic Department of Veterans Affairs (DVA)-accepted mental health conditions. RACGP President Dr Nicole Higgins said simple changes to the CVC would improve…

  • Education Training, Medical Health Aged Care
  • 24/04/2024
  • 16:17
La Trobe University

La Trobe awarded almost $1 million in research funding to improve antenatal care

A La Trobe University researcher has received almost $1 million in Federal Government funding to investigate ways to improve care for pregnant women. Six projects will share in $5 million from the National Health and Medical Research Council (NHMRC) Targeted Call for Research funding round, aimed at identifying how telehealth can be used most effectively and appropriately. Della Forster, Professor of Midwifery and Maternity Services Research with the Judith Lumley Centre and the Royal Women’s Hospital, received $999,585 for her team’s research into maternal and infant care. Professor Forster’s research looks at whether a combination of telehealth and face-to-face visits…

  • Medical Health Aged Care
  • 24/04/2024
  • 15:58
Dementia Australia

WALLY LEWIS WELCOMES GOVERNMENT PLEDGE TO FUND CTE SUPPORT

Wally Lewis AM, Dementia Australia and Connecters Australia Ambassador, today welcomed the comments from the Hon Anika Wells MP, Minister for Aged Care and Minister for Sport, in response to calls for $18M federal government funding for support services, education and awareness raising about concussion and chronic traumatic encephalopathy (CTE). “While we are yet to see the details, knowing the Minister has confirmed there will be something in the federal budget to address our calls is fantastic news,” Mr Lewis said. “On behalf of the Concussion and CTE Coalition and all people impacted by chronic traumatic encephalopathy I say thank…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.